Vivos Inc. (RDGL)
OTCMKTS · Delayed Price · Currency is USD
0.0528
-0.0040 (-7.04%)
Aug 20, 2026, 3:51 PM EST
Vivos Revenue
Vivos had revenue of $36.40K in the quarter ending June 30, 2026, with 142.67% growth. This brings the company's revenue in the last twelve months to $99.10K, up 91.52% year-over-year. In the year 2025, Vivos had annual revenue of $68.38K with 144.25% growth.
Revenue (ttm)
99.10K
Revenue Growth
+91.52%
P/S Ratio
267.71
Revenue / Employee
99.10K
Employees
1
Market Cap
26.53M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.38K | 40.38K | 144.25% |
| Dec 31, 2024 | 28.00K | 8.50K | 43.56% |
| Dec 31, 2023 | 19.50K | -17.00K | -46.57% |
| Dec 31, 2022 | 36.50K | 21.61K | 145.17% |
| Dec 31, 2021 | 14.89K | 7.89K | 112.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 36.88M |
| Kelyniam Global | 2.67M |
| BioElectronics | 1.61M |
| PetVivo Holdings | 1.18M |
| Tian'an Technology Group | 734.89K |
| Guided Therapeutics | 650.00K |
| Positron | 444.82K |
| CS Diagnostics | 204.00K |
Vivos News
- 2 days ago - Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center - GlobeNewsWire
- 24 days ago - Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction - GlobeNewsWire
- 24 days ago - Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - GlobeNewsWire
- 6 weeks ago - Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 2 months ago - Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing - GlobeNewsWire
- 2 months ago - Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 6 months ago - Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites - GlobeNewsWire
- 6 months ago - Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire